ArticlePediatric blood & cancer2017

A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).

Todd M Cooper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.